Dicerna Pharmaceuticals — Investor Presentation (April 2020)
28 slides from Dicerna Pharmaceuticals's investor presentation, Apr 1, 2020
Slide 1: Corporate Overview April 2020
Corporate Overview April 2020 © 2020 DICERNA
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation has been prepared by Dicerna Pharmaceuticals, Inc. (“we,” “us,” “our,” “Dicerna,” or the “Company”) and includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materi
Slide 3: Dicerna Vision and Strategy
Dicerna Vision and Strategy VISION STRATEGY Develop and commercialize our core Maximize the impact high-probability-of-success programs either alone or in collaboration of RNAi on medicine with partners Broadly enable the use of our GalXC™ technology by collaborating with therapeutic area leaders on
Slide 4: Dicerna Pipeline of Core and Collaborative Programs
Dicerna Pipeline of Core and Collaborative Programs TARGET DISCOVERY/ CLINICAL PROOF-OF- REGISTRATION DICERNA’S CANDIDATE PRECLINICAL INDICATION RESEARCH CONCEPT TRIALS TRIALS PRODUCT RIGHTS Nedosiran Primary 100% (DCR-PHXC) Hyperoxaluria RG6346* Hepatitis B Virus U.S. opt-in Core (DCR-HBVS) Program
Slide 5: The Foundation of Our Value
The Foundation of Our Value Delivery agents GalXC RNAi trigger • Proprietary, patented RNA interference (RNAi) technology with potential to extend to diverse tissues beyond the liver • Clinically compelling pharmaceutical properties Subcutaneously delivered → convenient administration Long duration
Slide 6: Multiple Upcoming Milestones
Multiple Upcoming Milestones* Nedosiran: First multidose results from PHYOX3 open-label clinical trial Nedosiran: PHYOX2 pivotal clinical trial enrollment completion – timing TBD RG6346: Phase 1 proof-of-concept data from all existing cohorts – August 2020 R&D Day GalXC: Present data for ext
Slide 7: Primary Hyperoxaluria
Primary Hyperoxaluria 7 ©2020 DICERNA
Slide 8: Primary Hyperoxaluria (PH)
Primary Hyperoxaluria (PH) A family of ultra-rare, life-threatening genetic disorders resulting in renal complications • Three known types of PH, each resulting from a mutation in one Known Types of Primary Hyperoxaluria of three different genes, cause enzyme deficiencies manifesting PH1 PH2 PH3 Gen
Slide 9: PHYOX1: Phase 1 Single-Dose Study of Nedosiran in PH1 and PH2 Participants
PHYOX1: Phase 1 Single-Dose Study of Nedosiran in PH1 and PH2 Participants 14/18 participants achieved normalization or near-normalization PHYOX1: Mean Urinary Oxalate Levels by Dose* 3.0 PHYOX1 open-label study included: 3.0 mg/kg • ) 6.0 mg/kg • 18 participants dosed: PH1 hr 2.5 (n=15) and PH2 (n=
Slide 10: PHYOX3: Open-Label Multidose Study of Nedosiran
PHYOX3: Open-Label Multidose Study of Nedosiran Analysis of preliminary interim data in March 2020 • PHYOX3 long-term, multidose, open-label rollover extension trial ongoing - 14 participants enrolled as of preliminary analysis - 4 participants had received at least three monthly doses of nedosiran
Slide 11: Nedosiran Clinical Trial Program to NDA Filing
Nedosiran Clinical Trial Program to NDA Filing Coordinated program of clinical trials to support a broad label in PH Pivotal Study Package Trial Description/Details Status PH Type Study 201: Pivotal, double-blind, randomized, placebo- Enrolling controlled trial (2:1 randomization) 1,2 n=~36 Monthly
Slide 12: Nedosiran: The Only RNAi Drug Candidate in Development for All PH Types
Nedosiran: The Only RNAi Drug Candidate in Development for All PH Types High unmet medical need across all PH types can be addressed Genetics of PH All Known PH1 PH2 PH3 Physician PH Types Patient & Education Caregiver Genetic prevalence 8.23 5.08 12.58 25.89 Support (per million) US 2,681 1,655 4,0
Slide 13: Chronic Hepatitis B Virus Infection
Chronic Hepatitis B Virus Infection 13 ©2020 DICERNA
Slide 14: Hepatitis B: A Severe, Global Unmet Medical Need
Hepatitis B: A Severe, Global Unmet Medical Need • Significant worldwide prevalence: ~292 million infected • Causes more than 887,000 deaths per year • Current treatments are rarely effective in achieving functional cures • Dicerna is collaborating with Roche to develop RG6346 (DCR-HBVS) and potenti
Slide 15: GalXC RNAi May Play a Key Role in Establishing a Functional HBV Cure
GalXC RNAi May Play a Key Role in Establishing a Functional HBV Cure Organization of the HBV genome enables effective RNAi targeting of multiple viral functions The Promise of RNAi for HBV Overlapping mRNAs and protein-coding regions enable targeting multiple HBV genes and proteins with a single Gal
Slide 16: Single-Dose GalXC-HBVS Reduced HBsAg to Below Lower Level of Detection
Single-Dose GalXC-HBVS Reduced HBsAg to Below Lower Level of Detection Striking pharmacodynamic differences between targeting in the S alone vs. S and X ORFs in preclinical model HDI-HBV HDI-HBV Plasmid Model Vehicle control • Immunohistochemical (cccDNA-dependent) staining of mouse liver sections f
Slide 17: RG6346 (DCR-HBVS) Clinical Program for Proof of Concept
RG6346 (DCR-HBVS) Clinical Program for Proof of Concept Includes placebo-controlled studies in both NUC-naïve and NUC-experienced patients Three-Part Study in Healthy Volunteers and Patients With Chronic HBV Infection Placebo-controlled, single-ascending-dose study Completed RG6346 dose cohorts: Gro
Slide 18: Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Alpha-1 Antitrypsin Deficiency- Associated Liver Disease 18 ©2020 DICERNA
Slide 19: Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Alpha-1 Antitrypsin Deficiency-Associated Liver Disease Most disease is caused by a single missense allele that forms aggregates in hepatocytes • Alpha-1 antitrypsin (A1AT): predominantly α1-Antitrypsin Deficiency produced in liver and secreted into blood Z mutation Glu342→Lys342 • Pi*ZZ genotype of
Slide 20: Activity of DCR-A1AT in Mice and Non-Human Primates
Activity of DCR-A1AT in Mice and Non-Human Primates Potency and duration of action Z-AAT Protein Knockdown in PiZ Mice A1AT Protein Knockdown in Monkeys PBS 3.0 mg/kg 3.0 mg/kg 10.0 mg/kg 10.0 mg/kg SEM SEM ± ± Mean Mean Mean Mean AAT Protein Protein Concentration AAT - Relative A1AT Protein Concent
Slide 21: DCR-A1AT Clinical Program for Proof of Concept
DCR-A1AT Clinical Program for Proof of Concept Part of larger clinical plan to achieve a rapid path to approval Two-part study: Single-ascending-dose (SAD) in healthy volunteers (HVs) and multiple-ascending-dose (MAD) in patients with A1AT deficiency-associated liver disease • HVs: SAD study, placeb
Slide 22: Corporate Collaborations
Corporate Collaborations 22 ©2020 DICERNA
Slide 23: Enhancing Value Through GalXC Collaboration Strategy
Enhancing Value Through GalXC Collaboration Strategy Successive collaborations increasing in scope and value $175M upfront $75M total annuals $200M upfront $50M equity • RG6346 (DCR- • 30+ potential HBVS) and multiple targets for liver- potential HBV- related CM diseases $100M upfront related target
Slide 24: Summary
Summary 24 ©2020 DICERNA Dicerna”
Slide 25: Elements of Portfolio Strategy
Elements of Portfolio Strategy We seek to generate value across the full spectrum of GalXC clinical applications Core Programs Collaborative Programs Highest Lower Resource Resource Investment Investment Cardiometabolic and Liver-related • Primary hyperoxaluria Diseases • HBV (U.S. opt-in) Chronic H
Slide 26: Strong Cash Position Provides Runway Through Commercialization
Strong Cash Position Provides Runway Through Commercialization Additional cash upside expected from collaboration milestones and potential royalties on product sales • Company well capitalized with approximately $720 million in unaudited cash, cash equivalents and marketable securities as of Februar
Slide 27: Multiple Upcoming Milestones
Multiple Upcoming Milestones* Nedosiran: First multidose results from PHYOX3 open-label clinical trial Nedosiran: PHYOX2 pivotal clinical trial enrollment completion – timing TBD RG6346: Phase 1 proof-of-concept data from all existing cohorts – August 2020 R&D Day GalXC: Present data for ext
Slide 28: Dicerna
Dicerna 28 ©2020 DICERNA
Dicerna Pharmaceuticals — Investor Presentation (April 2020) on 6ix